

*AMENDMENTS TO THE SPECIFICATION*

The sequence listing has been amended to correct a typographical error in SEQ ID NO: 28. A replacement sequence listing is enclosed herewith.

At page 1, line 3, insert:

INCORPORATION-BY-REFERENCE OF MATERIAL ELECTRONICALLY FILED

Incorporated by reference in its entirety herein is a computer-readable nucleotide/amino acid sequence listing submitted concurrently herewith and identified as follows: One 8706 Byte ASCII (Text) file named "229694sequence2," created on July 30, 2007.

Please replace paragraph 0042 with the following:

*Synthesis of cemadotin-peptide conjugates:* Gastrin- linker merged sequences VLALAE~~EEEE~~AYGW(Nle)DF (SEQ ID NO: 25) and ~~FLALAE~~FLALAEEEEEAYGW(Nle)DF (SEQ ID NO: 28) were prepared by automated solid-phase peptide synthesis on ABI Rink amide resin (Applied Biosystems, Foster City, CA) utilizing ABI 433 peptide synthesizer (Applied Biosystems, Foster City, CA) equipped with conductivity monitoring system. Standard Fast Fmoc chemistry with HBTU/HOBt activation mixture was used (see Chan et al., *Fmoc Solid Phase Peptide Synthesis - A Practical Approach*, Oxford University, New York (2000)). Double-coupling was used for the last four N-terminal residues. The purity of the products was confirmed by analytical cleavage and LC/MS. Cemadotin with free carboxy terminus (27.6 mg, 0.05 mmol) in 0.5 ml NMP was activated by treatment with HOAt (3.2 mg, 0.025 mmol), CIP (12.4 mg, 0.045 mmol) and DIPEA (0.017 ml, 0.1 mmol). The mixture was added to 157 mg resin containing 0.274 mmol protected VLALAE~~EEEE~~AYGW(Nle)DF (SEQ ID NO: 25) per 1 g (0.045 mmol) in 0.5 ml NMP. The mixture was incubated overnight, washed with NMP, dichloromethane (DCM) and dried. Cleavage from the resin and precipitation with ether was performed as described above. The product was purified by HPLC on C3 reverse phase column (10 x 300 mm) in the gradient of 0.05% trifluoroacetic acid/water-acetonitrile. Calculated molecular mass: 2260.3. Found by LC/MS - 2260.2.